Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer
| Autor: | Marco Gross-Langenhoff, Carsten-Henning Ohlmann |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Antineoplastic Agents Hormonal Depot Urology 030232 urology & nephrology 03 medical and health sciences Prostate cancer 0302 clinical medicine Leuprorelin Germany Internal medicine Daily practice medicine Humans Pooled data In patient Prospective Studies Adverse effect Aged Neoplasm Staging business.industry Prostatic Neoplasms medicine.disease Treatment Outcome Tolerability Delayed-Action Preparations 030220 oncology & carcinogenesis Leuprolide business medicine.drug |
| Zdroj: | Urologia Internationalis. 100:66-71 |
| ISSN: | 1423-0399 0042-1138 |
| Popis: | Introduction: We evaluated the efficacy and tolerability of 3- and 6-month leuprorelin acetate (LA) depot formulations (Eligard®, Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany. Materials and Methods: Data was pooled from 2 prospective, open-label, non-interventional studies in which 1,906 patients were treated for 12 months with either the 3-month (n = 633) or 6-month (n = 1,273) LA formulation. Results: Median prostate-specific antigen levels in the pooled patient population declined from 12.0 ng/mL at baseline to 0.5 ng/mL after 12 months. Prostate-specific antigen reduction was achieved in treatment-naïve and pre-treated patients. Adverse events were documented in 8.8% of patients. Conclusions: These pooled data from routine clinical practice in Germany indicate that LA 3- and 6-month depot injections can effectively reduce prostate-specific antigen levels in a broad patient population with advanced prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|